Continuation of Amiodarone Therapy Despite Type II Amiodarone-Induced Thyrotoxicosis
Abstract
Background Amiodarone is a powerful antiarrhythmic drug; however, its use may be complicated by thyrotoxicosis. When this occurs, clinicians must balance the continuation of amiodarone for antiarrhythmic purposes, and the discontinuation of treatment in order to prevent aggravation of the thyrotoxicosis. We studied the consequences of continuation or cessation of amiodarone in patients with type II amiodarone-induced thyrotoxicosis.Methods Consecutive patients who developed type II amiodarone-induced thyrotoxicosis between September 1997 and September 2000 were studied. Amiodarone was continued in patients with previous ventricular arrhythmia or supraventricular arrhythmia associated with severe haemodynamic changes and was withdrawn in the other patients. In patients with persistent, severe symptomatic thyrotoxicosis, corticosteroids were added to therapy.Results Thirteen patients were studied (nine with previous atrial fibrillation/flutter and four with ventricular tachycardia). Amiodarone treatment was continued in ten patients, including eight patients who received corticosteroids, and was temporarily halted in three patients. All patients recovered, with no difference in the duration of thyrotoxicosis between the two groups. Corticosteroid treatment was well tolerated and seemed to hasten the return to a euthyroid state (mean of 3.7 +/- 0.7 months vs 6.3 +/- 1.7 months). No recurrence of hyperthyroidism occurred during long-term follow-up.Conclusion In patients who require amiodarone, treatment may be safely continued despite the development of type II amiodarone-induced thyrotoxicosis.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Some patients with mild type 2 AIT (approximately 20%) resolve spontaneously without stopping amiodarone or administering corticosteroids.
“As noted above, some patients with mild type 2 AIT (approximately 20%) resolve spontaneously without stopping amiodarone or administering corticosteroids (606,607).”
From 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) · cites this paper as [607]
Cites
Thyroid hormone and the cardiovascular system.
Klein, I., & Ojamaa, K. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102153440707 · Cited by 2,300 · see citing works
Gregoratos, G., Abrams, J., Epstein, A. E., Freedman, R. A., Hayes, D. L., Hlatky, M. A., Kerber, R. E., Naccarelli, G. V., Schoenfeld, M. H., Silka, M. J., et al. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02528-7 · Cited by 1,272 · see citing works
Wazni, O. M., Marrouche, N. F., Martin, D. O., Verma, A., Bhargava, M., Saliba, W., Bash, D., Schweikert, R., Brachmann, J., Gunther, J., et al. (2005) · JAMA · doi:10.1001/jama.293.21.2634 · Cited by 1,121 · see citing works
Use of Transesophageal Echocardiography to Guide Cardioversion in Patients with Atrial Fibrillation
Klein, A. L., Grimm, R. A., Murray, R. D., Apperson-Hansen, C., ASINGER, R. W., Black, I. W., Davidoff, R., Erbel, R., Halperin, J. L., Orsinelli, D. A., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441901 · Cited by 952 · see citing works
The Effects of Amiodarone on the Thyroid
Martino, E., Bartalena, L., Bogazzi, F., & Braverman, L. E. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.2.0427 · Cited by 559 · see citing works
Electrical storm in patients with transvenous implantable cardioverter-defibrillators
Credner, S., Klingenheben, T., Mauß, O., Sticherling, C., & Hohnloser, S. H. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00495-1 · Cited by 375 · see citing works
Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism
Trip, M. D., Wiersinga, W. M., & Plomp, T. A. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90187-3 · Cited by 269 · see citing works
Bartalena, L., Brogioni, S., Grasso, L., Bogazzi, F., Burelli, A., & Martino, E. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.8.8768854 · Cited by 234 · see citing works
Nanthakumar, K., Epstein, A. E., Kay, G. N., Plumb, V. J., & Lee, D. S. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.08.054 · Cited by 216 · see citing works
Amiodarone-Induced Thyrotoxicosis
Daniels, G. H. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.1.7119 · Cited by 159 · see citing works
Eaton, S. E. M., Euinton, H. A., Newman, C. M., Weetman, A. P., & Bennet, W. M. (2002) · Clinical Endocrinology · doi:10.1046/j.0300-0664.2001.01457.x · Cited by 139 · see citing works
Iodine-Induced Thyrotoxicosis in Apparently Normal Thyroid Glands
Savoie, J. C., Jp, M., THOMOPOULOS, P., & Leger, F. A. (1975) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-41-4-685 · Cited by 129 · see citing works
Self-citationNichol, G., McAlister, F. A., Pham, B., Laupacis, A., Shea, B., Green, M. S., Tang, A., & Wells, G. (2002) · Heart · doi:10.1136/heart.87.6.535 · Cited by 123 · see citing works
Clinical and Prognostic Significance of Atrial Fibrillation in Acute Myocardial Infarction
Sakata, K., Kurihara, H., Iwamori, K., Maki, A., Yoshino, H., Yanagisawa, A., & Ishikawa, K. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00746-7 · Cited by 122 · see citing works
Iodine‐induced thyrotoxicosis: analysis of eighty‐five consecutive cases
Léger, A., MASSIN, J. P., Laurent, M. F., Vincens, M., Auriol, M., Helal, O. B., Chomette, G., & Savoie, J. C. (1984) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1984.tb01212.x · Cited by 109 · see citing works
Successful Treatment of Amiodarone-Induced Thyrotoxicosis
Osman, F., Franklyn, J. A., Sheppard, M. C., & Gammage, M. D. (2002) · Circulation · doi:10.1161/circ.105.11.1275 · Cited by 96 · see citing works
Bartalena, L., Wiersinga, W. M., Tanda, M. L., Bogazzi, F., Piantanida, E., Lai, A., & Martino, E. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02119.x · Cited by 88 · see citing works
The impact of arrhythmias in acute heart failure
Benza, R. L., Tallaj, J. A., Felker, G. M., et al. (2004) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2003.12.007 · Cited by 71 · see citing works
Chalvidan, T., Deharo, J., Dieuzaide, P., et al. (2000) · Pacing and Clinical Electrophysiology · doi:10.1111/j.1540-8159.2000.tb06772.x · Cited by 38 · see citing works
Davies, P. H. O., Franklyn, J. A., & Sheppard, M. C. (1992) · BMJ · doi:10.1136/bmj.305.6847.224 · Cited by 26 · see citing works
Amiodarone in the prevention and treatment of arrhythmia.
Auer, J., Berent, R., & Eber, B. (2002) · PubMed · Cited by 22 · see citing works
Manolis, A. G., Katsivas, A. G., Vassilopoulos, C. V., et al. (2002) · Journal of Interventional Cardiac Electrophysiology · doi:10.1023/a:1014188526158 · Cited by 22 · see citing works
Role of Amiodarone in the Era of the Implantable Cardioverter Defibrillator
Dorian, P., & Mangat, I. (2003) · Journal of Cardiovascular Electrophysiology · doi:10.1046/j.1540-8167.14.s9.22.x · Cited by 14 · see citing works
Rubboli, A., & Pasquale, G. D. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl348 · Cited by 8 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Ross, D. S., Burch, H. B., Cooper, D. S., Greenlee, M. C., Laurberg, P., Maia, A. L., Rivkees, S. A., Samuels, M., Sosa, J. A., Stan, M. N., et al. (2016) · Thyroid® · doi:10.1089/thy.2016.0229 · Cited by 2,938 · see citing works
“As noted above, some patients with mild type 2 AIT (approximately 20%) resolve spontaneously without stopping amiodarone or administering corticosteroids (606,607).”
BackgroundBartalena, L., Bogazzi, F., Chiovato, L., Hubalewska-Dydejczyk, A., Links, T. P., & Vanderpump, M. (2018) · European Thyroid Journal · doi:10.1159/000486957 · Cited by 264 · see citing works
Effects of amiodarone therapy on thyroid function
Cohen-Lehman, J., Dahl, P., Danzi, S., & Klein, I. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.225 · Cited by 157 · see citing works
Treatment of Amiodarone-Induced Thyrotoxicosis Type 2: A Randomized Clinical Trial
Eskes, S. A., Endert, E., Fliers, E., Geskus, R. B., Dullaart, R. P. F., Links, T. P., & Wiersinga, W. M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2390 · Cited by 78 · see citing works
Ahmed, S., Van Gelder, I. C., Wiesfeld, A. C. P., Van Veldhuisen, D. J., & Links, T. P. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04087.x · Cited by 72 · see citing works
Bogazzi, F., Bartalena, L., Tomisti, L., Rossi, G., Brogioni, S., & Martino, E. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1678 · Cited by 59 · see citing works
Stan, M. N., Sathananthan, M., Warnes, C. A., Brennan, M. D., Thapa, P., & Bahn, R. S. (2014) · Endocrine Practice · doi:10.4158/ep13059.or · Cited by 18 · see citing works
- Authors
- Uzan, L., Guignat, L., Meune, C., Mouly, S., Weber, S., Bertagna, X., Bertherat, J., Thomopoulos, P., & Duboc, D.
- Affiliations
- Hôpital Cochin (FR)
- Hôpital Lariboisière (FR)
- Corresponding author
- Meune, Christophe
- Venue
- Drug Safety
- Published
- 2006
- Volume
- 29
- Issue
- 3
- Pages
- 231-236
- ISSN
- 0114-5916 (ISSN-L)
- OpenAlex
- W2022208755
- Cited by
- 31
- References
- 24
- Citations by year
- 2024: 1 · 2023: 1 · 2022: 1 · 2021: 3 · 2020: 3 · 2019: 1 · 2018: 4 · 2016: 1 · 2015: 1 · 2014: 3 · 2013: 1
- FWCI
- 1.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drug Safety (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- amiodarone, corticosteroid therapy, atrial fibrillation, atrial flutter, ventricular tachycardia, hyperthyroidism, drug-induced thyroid dysfunction, antiarrhythmic drug withdrawal
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Amiodarone, Anti-Arrhythmia Agents, Female, Humans, Male, Middle Aged, Prospective Studies, Tachycardia, Supraventricular, Thyrotoxicosis, Ventricular Fibrillation, Databases, Factual, Treatment Outcome, Practice Guidelines as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
